Q-omics provides the consensus-scored TMEM144 profile across patient tissues and cancer cell-line models. TMEM144 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMEM144 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TMEM144 RNA expression shows 21,424 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where TMEM144 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM144 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM144 survival associations across molecular data types. TMEM144 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM144 RNA expression–survival associations across cancer types. High TMEM144 expression shows unfavorable associations in HNSC, LUAD, LAML and THYM, but favorable associations in BRCA and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMEM144 RNA expression.
This table summarizes TMEM144 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM144. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM144 shows lower tumor expression in LUSC, THCA and COAD and higher tumor expression in KIRC, KIRP and STAD. The KIRC box plot shows higher TMEM144 RNA expression in tumor versus normal tissue (log2 FC = +0.874, t-test p < 0.001).
This table shows molecular features associated with TMEM144 in patient tissues and cancer cell lines. In patient samples, TMEM144 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM144 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
